Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Neonc Technologies, Inc.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06047379CT.gov Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | — | Recruiting | — | — | — |
NCT05489211CT.gov Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | — | Recruiting | — | — | — |
NCT04887831CT.gov Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab | — | Terminated | — | — | — |
NCT04452214CT.gov A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors | — | Completed | — | — | — |
NCT04198766CT.gov Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | — | Active Not Recruiting | — | — | — |
NCT03582475CT.gov Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | — | Active Not Recruiting | — | — | — |
NCT03520231CT.gov Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases | — | Completed | — | — | — |
NCT03317496CT.gov Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT03288545CT.gov A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer | — | Terminated | — | — | — |
NCT02853305CT.gov Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) | — | Completed | — | — | — |
Show 3 more trialsShow fewer
NCT02665039CT.gov A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function | — | Completed | — | — | — |
NCT01366144CT.gov Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | — | Active Not Recruiting | — | — | — |
NCT01328574CT.gov TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Urothelial Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Carboplatin (this asset) | Neonc Technologies, Inc. | P3 | BB · 65 |
| Cyclophosphamide | Beijing Biotech | P3 | BB |
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) | Vasgene Therapeutics, Inc | P2/3 | BB |
| Pembrolizumab | Sutro Biopharma, Inc. | P3 | BB |
| Durvalumab | Alliance for Clinical Trials in Oncology | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Nagoya University | P3 | BB |
| Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer | Eli Lilly and Company | P3 | BB |
| Retifanlimab | Incyte Corporation | P2 | BB |
| Docetaxel | NuCana plc | P3 | BB |
+42 more in the Urothelial Carcinoma cohort
Other indications for Carboplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Large Cell Carcinoma | — | P4 | A · 80 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 76 |
| Non-Small Cell Squamous Lung Carcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CyclophosphamideBeijing BiotechBB
- Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Vasgene Therapeutics, IncBB
- PembrolizumabSutro Biopharma, Inc.BB
- DurvalumabAlliance for Clinical Trials in OncologyBB
- Cis-Diamminedichloroplatinum IiNagoya UniversityBB
Citation
Floatz Terminal. Carboplatin in Urothelial Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/carboplatin-urothelial-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →